As of 2025-05-17, the EV/EBITDA ratio of Avidity Biosciences Inc (RNA) is -9.13. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Avidity's latest enterprise value is 3,437.91 mil USD. Avidity's TTM EBITDA according to its financial statements is -376.41 mil USD. Dividing these 2 quantities gives us the above Avidity EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.3x - 13.4x | 13.3x |
| Forward P/E multiples | 18.2x - 29.1x | 19.0x |
| Fair Price | (54.89) - (40.09) | (48.62) |
| Upside | -280.9% - -232.1% | -260.2% |
| Date | EV/EBITDA |
| 2025-05-15 | -8.69 |
| 2025-05-14 | -8.51 |
| 2025-05-13 | -8.98 |
| 2025-05-12 | -8.81 |
| 2025-05-09 | -8.34 |
| 2025-05-08 | -8.60 |
| 2025-05-07 | -7.80 |
| 2025-05-06 | -7.82 |
| 2025-05-05 | -9.75 |
| 2025-05-02 | -9.73 |
| 2025-05-01 | -9.88 |
| 2025-04-30 | -9.87 |
| 2025-04-29 | -9.71 |
| 2025-04-28 | -9.41 |
| 2025-04-25 | -9.29 |
| 2025-04-24 | -9.32 |
| 2025-04-23 | -9.24 |
| 2025-04-22 | -8.85 |
| 2025-04-21 | -8.55 |
| 2025-04-17 | -7.95 |
| 2025-04-16 | -7.66 |
| 2025-04-15 | -7.96 |
| 2025-04-14 | -8.03 |
| 2025-04-11 | -7.61 |
| 2025-04-10 | -7.14 |
| 2025-04-09 | -7.36 |
| 2025-04-08 | -7.13 |
| 2025-04-07 | -7.57 |
| 2025-04-04 | -7.92 |
| 2025-04-03 | -8.41 |
| 2025-04-02 | -8.95 |
| 2025-04-01 | -7.98 |
| 2025-03-31 | -8.87 |
| 2025-03-28 | -9.53 |
| 2025-03-27 | -9.84 |
| 2025-03-26 | -9.68 |
| 2025-03-25 | -9.69 |
| 2025-03-24 | -10.08 |
| 2025-03-21 | -9.29 |
| 2025-03-20 | -9.29 |
| 2025-03-19 | -9.57 |
| 2025-03-18 | -9.18 |
| 2025-03-17 | -10.25 |
| 2025-03-14 | -9.38 |
| 2025-03-13 | -9.70 |
| 2025-03-12 | -9.86 |
| 2025-03-11 | -8.89 |
| 2025-03-10 | -9.03 |
| 2025-03-07 | -9.11 |
| 2025-03-06 | -9.13 |